Star Housing Fin (539017)
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹48.92 |
| Market Cap | ₹386.29 Cr |
| P/E Ratio | 8.11 |
| ROCE | 12.1% |
| ROE | 4.74% |
| Dividend Yield | 1.47% |
| Profit Growth | -75.98% |
| Debt/Equity | — |
| Sales Growth | 7.45% |
| 52-Week Range | ₹3.67 — ₹48.92 |
| Sector | Finance |
| Book Value | ₹20.06 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹48.92, Star Housing Fin has had a remarkable run—from ₹3.67 to the top of its 52-week range—but my first thought is the blunt one: am I buying earnings or hopes? Book value is ₹20.06, so paying ₹48.92 means 2.44 times book. For a housing finance company with an ROE of only 4.74%, that is a rich price; you need a wide moat and strong returns when you pay above book. I do not see that moat. Sales grew 7.45%, respectable but not exciting, while profit fell 75.98%. The latest quarter shows sales of ₹26 Cr and net profit of ₹0 Cr—the engine has stalled. The reported P/E of 8.11 looks cheap at first glance, but it sits uneasily with the ROE of 4.74% and the zero quarterly profit, so it should not be trusted without clarity on one-off items. The Piotroski F-Score of 4 out of 9 reinforces caution: financial health is mediocre. ROCE of 12.10% is decent, but it is not a franchise. Debt-to-equity is not disclosed, and for a lender that is a serious gap. A 1.47% dividend offers some comfort, but it is thin compensation for the risks. This feels like a cyclical business; housing finance moves with credit and real-estate cycles. If the cycle turns upward, profits could recover sharply, but I need evidence before calling it a turnaround. Graham said price is what you pay, value is what you get. At 2.44 times book for a 4.74% return on equity, I worry the price already contains a lot of optimism. Let the business prove itself first.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer